Skip to main content
Rebecca (Suk) Heist, MD, Oncology, Boston, MA

Rebecca Suk (Suk) Heist MD

Hematologic Oncology, Thoracic Cancer


Associate Professor of Medicine, Massachusetts General Hospital

Join to View Full Profile
  • 32 Fruit StYawkey 7BBoston, MA 02114

  • Phone+1 617-724-4000

  • Fax+1 617-726-0453

Dr. Heist is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

Summary

  • Dr. Rebecca Heist is an oncologist in Boston, MA and is affiliated with Massachusetts General Hospital. She received her medical degree from Harvard Medical School and has been in practice 18 years. She specializes in thoracic cancer and is experienced in the treatment of lung cancer, with a special focus on clinical trials of novel agents.

Education & Training

  • Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer Institute
    Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2002 - 2005
  • Mass General Brigham/Massachusetts General Hospital
    Mass General Brigham/Massachusetts General HospitalResidency, Internal Medicine, 1999 - 2002
  • Harvard Medical School
    Harvard Medical SchoolClass of 1999

Certifications & Licensure

  • MA State Medical License
    MA State Medical License 2001 - 2026
  • Medical Oncology
    American Board of Internal Medicine Medical Oncology

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Oxford University Press Has Registered This DOI Pre-Publication  
    R S Heist, Z Piotrowska, C G Azzoli, A T Shaw, I T Lennes, L V Sequist, J F Gainor, Oxford University Press

Lectures

  • c-Met expression and response to telisotuzumab vedotin (teliso-v) in patients with non-small cell lung cancer. 
    2019 ASCO Annual Meeting - 6/1/2019

Press Mentions

  • Coronavirus Slowing Critical Cancer Research, Screenings
    Coronavirus Slowing Critical Cancer Research, ScreeningsDecember 21st, 2020
  • Agios Presents Data from Single Agent Dose-Escalation Arm of Phase 1 Study of AG-270, a MAT2A Inhibitor, in Patients with MTAP-Deleted Tumors
    Agios Presents Data from Single Agent Dose-Escalation Arm of Phase 1 Study of AG-270, a MAT2A Inhibitor, in Patients with MTAP-Deleted TumorsOctober 27th, 2019
  • Capmatinib Trial Targets New Molecular Subsets of Patients in NSCLC
    Capmatinib Trial Targets New Molecular Subsets of Patients in NSCLCJuly 4th, 2016
  • Join now to see all

Professional Memberships

Viewing the full profile is available to verified healthcare professionals only.

Find your profile and take control of your online presence: